Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director Ghent, Belgium – June 10, 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and […]
Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer –New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– Ghent, Belgium – June 3, 2020 – Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective […]
Confo Therapeutics reports grant of two key patents for ConfoBodies™ Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBody™ patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan Steyaert (VIB-VUB), their first-named […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.